Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness

Clinical Endocrinology

Volumn 85, Issue 2, 2016, Pages 239-246

  Gava, Giulia ^a   Cerpolini, Silvia ^a   Martelli, Valentina ^a   Battista, Giuseppe ^a   Seracchioli, Renato ^a   Meriggiola, Maria Cristina ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYPROTERONE ACETATE; ESTRADIOL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUPRORELIN; LUTEINIZING HORMONE; PARATHYROID HORMONE; PROLACTIN; TESTOSTERONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BODY COMPOSITION; BONE DENSITY; BONE METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MALE TO FEMALE TRANSGENDER; OBSERVATIONAL STUDY; PILOT STUDY; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL;

EID: 84978300267     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.13050     Document Type: Article

References (25)

1. Hembree, W.C., Cohen-Kettenis, P., Delemarre-van de Waal, H.A. et al. (2009) Endocrine treatment of transsexual persons: an Endocrine Society Clinical Practice guideline. Journal of Clinical Endocrinology and Metabolism, 94, 3132–3154.
2. Meriggiola, M. C. & Gava, G. (2015) Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clinical Endocrinology, 83, 607–615.
3. Savidou, I., Deutsch, M., Soultati, A.S. et al. (2006) Hepatotoxicity induced by cyproterone acetate: a report of three cases. World Journal of Gastroenterology, 12, 7551–7555.
4. Van Kesteren, P.J., Asscheman, H., Megens, J.A. et al. (1997) Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clinical Endocrinology, 47, 337–342.
5. Seal, L.J., Franklin, S., Richards, C. et al. (2012) Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. Journal of Clinical Endocrinology and Metabolism, 97, 4422–4428.
6. Gil, M., Oliva, B., Timoner, J. et al. (2011) Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. British Journal of Clinical Pharmacology, 72, 965–968.
7. Cebula, H., Pham, T.Q., Boyer, P. et al. (2010) Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient. Acta Neurochirurgica, 52, 1955–1956.
8. Gazzeri, R., Galarza, M. & Gazzeri, G. (2007) Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. New England Journal of Medicine, 357, 2411–2412.
9. Bergoglio, M.T., Gómez-Balaguer, M., Almonacid Folch, E. et al. (2012) Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual. Endocrinologia Nutricion, 60, 264–267.
10. Wilson, A.C., Meethal, S.V., Bowen, R.L. et al. (2007) Leuprolide acetate: a drug of diverse clinical applications. Expert Opinion on Investigational Drugs, 16, 1851–1863.
11. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th edn. Arlington, VA, American Psychiatric Association. Available from: dsm.psychiatryonline.org (accessed 1 September 2014).
12. Lohman, T.G. (1992) Advances in body composition assessment. Current issues in exercise science series (monograph 3). Champaign, IL: Human Kinetics.
13. Beck, A.T., Steer, R.A. & Brown, G.K. (1996) Beck Depression Inventory, 2nd Edn Manual. The Psychological Corporation Harcourt Brace & Company, San Antonio, TX.
14. Cohen-Kettenis, T. & van Goozen, S.H. (1997) Sex reassignment of adolescent transsexuals: a follow-up study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 263–271.
15. McHorney, C.A., War, J.E., Lu, J.F.R. et al. (1994) The MOS 36-Item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care, 32, 40–66.
16. Gooren, L.J., Harmsen-louman, W. & Van Kessel, H. (1985) Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction. Clinical Endocrinology, 22, 201–207.
17. Asscheman, H., Gooren, L.J., Assies, J. et al. (1988) Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals. Clinical Endocrinology, 25, 583–588.
18. Cunha, F.S., Domenice, S., Câmara, V.L. et al. (2015) Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy. Andrologia, 47, 680–684.
19. Bunck, M.C., Debono, M., Giltay, E.J. et al. (2009) Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages. BMJ Case Reports, doi:10.1136/bcr.02.1589.
20. García-Malpartida, K., Martín-Gorgojo, A., Rocha, M. et al. (2010) Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual. Fertility and Sterility, 94, 1097.e13–e15.
21. Lapauw, B., Taes, Y., Simoens, S. et al. (2008) Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone, 43, 1016–1021.
22. Haraldsen, I.R., Haug, E., Falch, J. et al. (2007) Cross-sex pattern of bone mineral density in early onset gender identity disorder. Hormones and Behavior, 52, 334–343.
23. T'Sjoen, G., Weyers, S., Taes, Y. et al. (2009) Prevalence of low bone mass in relation to estrogen treatment and body composition in male-to-female transsexual persons. Journal of Clinical Densitometry, 12, 306–313.
24. Smith, M.R., Lee, H., McGovern, F. et al. (2008) Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer, 112, 2188–2194.
25. Poyet, P. & Labrie, F. (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Molecular and Cellular Endocrinology, 42, 283–288.